Drug Profile
Research programme: anti-cancer peptides - Riptide Bioscience
Alternative Names: CD206 targeting peptides - Riptide Bioscience; RP-182Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Riptide Bioscience
- Developer National Cancer Institute (USA); Riptide Bioscience
- Class Peptides
- Mechanism of Action Macrophage inhibitors; Mannose receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Pancreatic cancer
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Pancreatic-cancer(Combination therapy) in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 14 Feb 2020 Research programme: anti-cancer peptides - Riptide Bioscience is available for licensing as of 14 Feb 2020. www.riptidebio.com